15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $4.7B | $836M | 60.1% | 19.6% | $1.1B | — | $918M |
| 2024 | $4.0B | $576M | 60.5% | 14.9% | $631M | — | $606M |
| 2023 | $3.6B | $542M | 63.2% | 16.5% | $512M | — | $566M |
| 2022 | $2.9B | $341M | 64.7% | 13.4% | $305M | — | $642M |
| 2021 | $2.4B | $217M | 68.6% | 10.9% | $53M | — | $1.1B |
| 2020 | $1.9B | $550M | 66.4% | 15.5% | $277M | — | $818M |
| 2019 | $1.5B | $101M | 63.1% | 9.6% | $135M | — | $446M |
| 2018 | $1.0B | -$127M | 64.4% | -18.1% | $56M | — | $1.1B |
| 2017 | $719M | -$50M | 68.5% | -5.9% | $26M | — | $442M |
| 2016 | $573M | -$66M | 66.0% | -11.1% | $500000 | — | $95M |
| 2015 | — | -$58M | — | — | $16M | — | $86M |
| 2014 | — | -$22M | — | — | $7M | $5M | $72M |
| 2013 | — | -$30M | — | — | -$6M | $7M | $43M |
| 2012 | — | -$55M | — | — | -$43M | $7M | $8M |
| 2011 | — | -$45M | — | — | -$38M | — | $3M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1.2B | $200M | 62.9% | 21.4% | $449M | — | $1.1B |
| Dec '25 | $1.3B | $267M | 62.9% | 25.6% | $192M | — | $918M |
| Sep '25 | $1.2B | $284M | 60.5% | 20.1% | $579M | — | $1.8B |
| Jun '25 | $1.2B | $180M | 59.5% | 18.4% | $209M | — | $1.2B |
| Mar '25 | $1.0B | $105M | 56.9% | 12.9% | $97M | — | $905M |
| Dec '24 | $1.1B | $152M | 58.9% | 17.0% | $177M | — | $606M |
| Sep '24 | $994M | $135M | 59.7% | 15.3% | $88M | — | $621M |
| Jun '24 | $1.0B | $144M | 62.4% | 15.7% | $213M | — | $939M |
| Mar '24 | $921M | $146M | 61.0% | 11.0% | $152M | — | $851M |
| Dec '23 | $1.0B | $256M | 63.5% | 21.0% | $81M | — | $566M |
| Sep '23 | $975M | $121M | 63.9% | 21.1% | $219M | — | $644M |
| Jun '23 | $871M | $116M | 62.7% | 14.7% | $131M | — | $1.2B |
| Mar '23 | $742M | $49M | 62.4% | 6.4% | $81M | — | $623M |
| Dec '22 | $815M | $92M | 66.4% | 15.4% | $69M | — | $642M |
| Sep '22 | $770M | $101M | 64.2% | 19.2% | $185M | — | $698M |
| Jun '22 | $696M | $51M | 64.6% | 11.1% | $81M | — | $735M |
| Mar '22 | $629M | $97M | 63.3% | 6.6% | -$31M | — | $716M |
| Dec '21 | $698M | -$5M | 67.7% | 0.1% | $26M | — | $1.1B |
| Sep '21 | $650M | $87M | 68.7% | 18.2% | $139M | — | $1.4B |
| Jun '21 | $595M | $78M | 70.1% | 17.0% | -$40M | — | $1.2B |
How the market has priced DXCM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, DexCom's revenue has grown 19.3% per year, and net income grown 8.8% per year. These are computed facts, not advice.
As of FY2025, DexCom reported — of total debt against $918M of cash; operating income covered interest expense 50×.
In FY2025, gross margin was 60.1%, operating margin 19.6%, and net margin 17.9%.
As of Jun '26, DexCom traded at a price-to-earnings ratio of about 31.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.